Moderna says Phase 2/3 trials of its COVID-19 vaccines for children one for those aged six months to 2 years and another for those aged between 2 and 6 showed a "robust neutralizing antibody response" along with "a favorable safety profile."
Moderna says Phase 2/3 trials of its COVID-19 vaccines for children one for those aged six months to 2 years and another for those aged between 2 and 6 showed a "robust neutralizing antibody response" along with "a favorable safety profile."